AstraZeneca spikes; receives approval for importing diabetes drug
DSIJ Intelligence / 18 Oct 2017
The stock of AstraZeneca Pharma India was trading higher by 3.47% at Rs. 979.85 per share. The stock has shown a trend reversal after two days of consecutive fall.
The stock of AstraZeneca Pharma India was trading higher by 3.47% at Rs. 979.85 per share. The stock opened at Rs. 974.00 on Wednesday. The stock has shown a trend reversal after two days of consecutive fall.
The company informed the exchanges that it has received import and market permission through Form 45 from the Drug Controller General of India (DCGI) for FDC (Xigduo XR) of Dapagliflozin plus Metformin Hydrochloride, extended-release tablets.
The medication Xigduo XR tablet is indicated for the treatment of patients with Type 2 diabetes mellitus as an adjunct to diet and exercise regime to improve glycemic levels. The mediation will provide physicians with an advanced treatment option for managing potential weight loss and reduce the risk of hypoglycemia.
AstraZeneca Pharma India Limited is biopharmaceutical company that engages in manufacturing, sales and marketing activities of the company. The company has an extensive portfolio in various areas of healthcare including cardiovascular, metabolic diseases, oncology and respiratory.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.